Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation
By: L.L.W. Cooling, J. Sherbeck, J.C. Mowers and S.L. Hugan
Paid access
|Oct 2019Authors
L.L.W. Cooling
Transfusion Medicine, University of Michigan Hospitals, Department of Pathology, 2F225 UH-Blood Bank, Ann Arbor, MI, United States
J. Sherbeck
Pathology House Officer IV, University of Michigan, Department of Pathology, Ann Arbo, United States
J.C. Mowers
Pathology House Officer III, University of Michigan, Department of Pathology, Ann Arbo, United States
S.L. Hugan
Immunohematology Reference Laboratory, University of Michigan Hospitals, Ann Arbor, MI, United States
DOI: https://doi.org/10.21307/immunohematology-2019-004 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 15 - 21
Published on: Oct 9, 2019
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2019 L.L.W. Cooling, J. Sherbeck, J.C. Mowers, S.L. Hugan, published by American National Red Cross
This work is licensed under the Creative Commons License.